Karyopharm TherapeuticsKPTI +0.15%52 Quick Ratio is 1.05 as of Mar. 2026, which is 77% below its 10-year median of 4.60. GuruFocus rates KPTI with a GF Score™ of 52/100 and a GF Value™ of $6.39 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,412 Biotechnology companies, Karyopharm Therapeutics ranks worse than 79.96% on this metric.
Karyopharm Therapeutics has a quick ratio of 1.05. It generally indicates good short-term financial strength.
The historical rank and industry rank for Karyopharm Therapeutics's Quick Ratio or its related term are showing as below:
KPTI'
s Quick Ratio Range Over the Past 10 Years
Min: 0.94 Med: 4.6 Max: 8.71
Current: 1.05
During the past 13 years, Karyopharm Therapeutics's highest Quick Ratio was 8.71. The lowest was 0.94. And the median was 4.60.
KPTI's Quick Ratio is ranked worse than 79.96% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs KPTI: 1.05
Karyopharm Therapeutics (NAS:KPTI) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Karyopharm Therapeutics Quick Ratio Related Terms
Karyopharm Therapeutics Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Karyopharm Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Karyopharm Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Karyopharm Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics (KPTI) has a Quick Ratio of 1.05 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Karyopharm Therapeutics and its competitors. This is 77% below median its historical median of 4.60. Over the past decade, Karyopharm Therapeutics' Quick Ratio has ranged from 0.94 to 8.71. According to the industry distribution chart, Karyopharm Therapeutics ranks #1129 out of 1412 companies in the Biotechnology industry, placing it in the top 80%.
Is Karyopharm Therapeutics' Quick Ratio too high?
Karyopharm Therapeutics' current Quick Ratio of 1.05 is 77% below median its 10-year median of 4.60. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 8.71. The Biotechnology industry median Quick Ratio is 3.60. Karyopharm Therapeutics' value of 1.05 is 70.8% below this industry median. Based on the distribution chart, Karyopharm Therapeutics ranks #1129 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Karyopharm Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Quick Ratio compare to CHRS and TARA?
According to the Biotechnology industry distribution chart, Karyopharm Therapeutics ranks #1129 out of 1412 companies for Quick Ratio. This places Karyopharm Therapeutics in the lower half of its industry. The industry median Quick Ratio is 3.60. Karyopharm Therapeutics' value of 1.05 is 70.8% below this benchmark. Historically, Karyopharm Therapeutics' own Quick Ratio has ranged from 0.94 to 8.71 over the past decade. While the company's 10-year median is 4.60 vs. the industry median of 3.60, Karyopharm Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Karyopharm Therapeutics's current Quick Ratio of 1.05 is 70.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Karyopharm Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Karyopharm Therapeutics's current Quick Ratio is 1.05, which is 77% below median its own 10-year median of 4.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.39, compared to a current price of $9.77 — trading 52.9% above its estimated fair value. The current Quick Ratio is 1.05, which is 77% below median its 10-year median of 4.60 and 70.8% below the Biotechnology industry median of 3.60. Karyopharm Therapeutics' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current Quick Ratio is 1.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?
Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued.
The current stock price of $9.77 is trading 52.9% above its estimated GF Value™ of $6.39.
GuruFocus considers Karyopharm Therapeutics to be Significantly Overvalued.
Key valuation signals for KPTI:
Quick Ratio: 1.05 (77% below median its 10-year median of 4.60)
GF Value™: $6.39 vs. price of $9.77 (52.9% above fair value)
Industry Position: 70.8% below the Biotechnology median (#1129 of 1412)
No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
52GF Score
Get the complete analysis for KPTI
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KPTI has been successfully added to your 
